{"id":"W4296532403","doi":"10.1016/s2152-2650(22)01303-9","title":"AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; McGill University; University of Toronto; Jewish General Hospital","funders":"","keywords":"Venetoclax; Medicine; Azacitidine; Cohort; Internal medicine; Neutropenia; Myeloid leukemia; Myeloid; Myelodysplastic syndromes; Oncology; Hypomethylating agent; Tolerability; Leukemia; Gastroenterology; Chemotherapy; Adverse effect; Chronic lymphocytic leukemia; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001568869,0.0009692934,0.001770763,0.0003425565,0.0003468883,0.0008207697,0.0006980354,0.0009186701,0.003883495],"category_scores_gemma":[0.001448846,0.0004376099,0.001448603,0.0002583638,0.0006261596,0.0005827228,0.0003089457,0.002522677,0.0006871478],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008034433,"about_ca_system_score_gemma":0.00123135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001096065,"about_ca_topic_score_gemma":0.003178864,"domain_scores_codex":[0.9993098,0.0004079153,0.00003055215,0.00008928328,0.00004854397,0.000114086],"domain_scores_gemma":[0.9987769,0.000328063,0.0001582802,0.0001160171,0.00005881447,0.0005620139],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7605955,0.03205205,0.02228049,0.0006190751,0.002659027,0.0003793103,0.0002491718,0.002548069,0.04687579,0.0003062336,0.006104658,0.1253306],"study_design_scores_gemma":[0.6243601,0.3101225,0.04830256,0.00004891954,0.00193497,0.0004548955,0.0000707695,0.0009558631,0.007502295,0.0002578855,0.00595325,0.00003597372],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889755,0.002708363,0.0005162859,0.001029087,0.0001609301,0.001114651,0.0026734,0.0001181661,0.002703728],"genre_scores_gemma":[0.9854547,0.001607785,0.00156794,0.001312426,0.0002938597,0.0009755089,0.005666364,0.00004302993,0.003078528],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003883495,"threshold_uncertainty_score":0.01299155,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02956475525237945,"score_gpt":0.3289052591413446,"score_spread":0.2993405038889651,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}